Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate
The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026 Over 420 million people around the globe currently have diabetes, with the American Diabetes Association recommending that all adults screen for the condition every three years Nemaura Medical has sought to capitalize on the blood glucose monitoring sector’s phenomenal growth rate through the launch of its proprietary body worn continuous glucose sensor in both the diabetes sector and consumer healthcare sector. The company’s flagship sugarBEAT(R) device provides diabetic and pre-diabetic patients with the ability…